- Home
- JNVR vs NCNA Comparison
JNVR vs NCNA Comparison
Compare JNVR & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JNVR
- NCNA
- Stock Information
- Founded
- JNVR 2018
- NCNA 1997
- Country
- JNVR United States
- NCNA United Kingdom
- Employees
- JNVR N/A
- NCNA N/A
- Industry
- JNVR Finance: Consumer Services
- NCNA Biotechnology: Pharmaceutical Preparations
- Sector
- JNVR Finance
- NCNA Health Care
- Exchange
- JNVR Nasdaq
- NCNA Nasdaq
- Market Cap
- JNVR 5.1M
- NCNA 4.4M
- IPO Year
- JNVR 2023
- NCNA 2017
- Fundamental
- Price
- JNVR $0.49
- NCNA $1.27
- Analyst Decision
- JNVR
- NCNA Buy
- Analyst Count
- JNVR 0
- NCNA 2
- Target Price
- JNVR N/A
- NCNA $25.00
- AVG Volume (30 Days)
- JNVR 1.2M
- NCNA 130.4K
- Earning Date
- JNVR 11-06-2024
- NCNA 12-03-2024
- Dividend Yield
- JNVR N/A
- NCNA N/A
- EPS Growth
- JNVR N/A
- NCNA N/A
- EPS
- JNVR N/A
- NCNA N/A
- Revenue
- JNVR $1,820,969.00
- NCNA N/A
- Revenue This Year
- JNVR N/A
- NCNA N/A
- Revenue Next Year
- JNVR N/A
- NCNA N/A
- P/E Ratio
- JNVR N/A
- NCNA N/A
- Revenue Growth
- JNVR N/A
- NCNA N/A
- 52 Week Low
- JNVR $0.42
- NCNA $1.25
- 52 Week High
- JNVR $1.84
- NCNA $19.40
- Technical
- Relative Strength Index (RSI)
- JNVR 39.92
- NCNA 27.73
- Support Level
- JNVR $0.43
- NCNA $1.26
- Resistance Level
- JNVR $0.69
- NCNA $1.66
- Average True Range (ATR)
- JNVR 0.09
- NCNA 0.09
- MACD
- JNVR -0.01
- NCNA 0.02
- Stochastic Oscillator
- JNVR 16.78
- NCNA 4.88
About JNVR Janover Inc.
Janover Inc is a B2B fintech marketplace providing a platform for commercial property borrowers and lenders. It provides a technology platform that connects commercial mortgage borrowers looking for debt to refinance, build, or buy commercial property including apartment buildings to commercial property lenders including banks, credit unions, REITs, debt funds, and more looking to deploy capital into commercial mortgages. The firm caters to two consumer segments: lenders and borrowers. It derives the majority of its revenue from transaction fees.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.